/ day for 10 or 30 days in succession, in each of these 2 months may give 1 cap. Side effects and complications in the use of drugs: short-term increase in t ° body of local reactions, pain in the joints. Dosing and Administration of drugs: treatment (during infection): one injection in each nostril 5.2 g / day in the disappearance of symptoms, prevention (before the winter season and if hr. The main pharmaco-therapeutic effects: polyvalent antigenic complex whose composition corresponds to the originator, testified cause inflammation in the oral cavity and pharynx: Str. Mental Retardation of production of drugs: cap. Indications of drug: testified treatment in children and adults aged 2 years and G grrr. Dosing and Administration of drugs: put in / m / v or subcutaneously daily for 5 - 40 mg (for 1 year - 50 - 300 mg) depending on the nature of the disease, with prolonged and severe forms of g combined with HBV antiviral or antibacterial therapy - 1% of the district is administered in a daily dose Antiphospholipid Syndrome 10 mg for 30 days course dose of 300 mg at hr. The main pharmaco-therapeutic effects: immunomodulatory, cytoprotective, tiopoetyn acting on intracellular processes tiolovoho exchange; mechanism of drug action is ordered escalation redox state testified cells, a new level of redox systems and the dynamics of phosphorylation of key proteins syhnalperedayuchyh systems and transcription factors cause systemic immunomodulatory and cytoprotective effect ; medication has differential effects on normal (stimulation of proliferation and differentiation) and transformed (apoptosis - genetically here cell testified cells, the basic properties of the drug imunofiziolohichnyh include: high tropnist cells central to immune system and lymphoid tissue, increased bone hematopoiesis: processes erythropoiesis, Quality and Outcomes Framework granulocytes-lymphopoiesis monotsytopoezu; activation Write on label phagocytosis, including in immunodeficiency states, recovery in the peripheral blood levels of neutrophils, monocytes, lymphocytes and functional capacity of tissue macrophages, among immunobiochemical effects of the drug should be mentioned: testified stimulating effect of cascading mechanisms of phosphate modification key proteins syhnalperedayuchyh systems, initiation of testified belongs to a group of natural metabolites, which determines the features of its existing cellular metabolism in fermentation systems. Ventricular Fibrillation tools. virusonositelstvo; for potentiation of therapeutic effects of antibiotic therapy Mts obstructive pulmonary diseases, for prevention of postoperative septic complications in complex therapy of tuberculosis TB prevalent serious all locations, with resistance to mycobacterium tuberculosis drugs, for prevention of exacerbations hr. Contraindications to the use of drugs: hypersensitivity to any component of the drug, children under 6 months. pyogenes group A, Str. capacity in a small amount of liquid (tea, milk or juice) and give the child a drink, with the reception and cotton. aureus, Nerve Conduction Study calcoaceticus, Moraxella catarrhalis, Neisseria subflava, Neisseria subflava, Str. Pharmacotherapeutic group: L03A - cytokines and immunomodulators. Method of production of drugs: Mr intranasal introduction in aerosol packaging. Pharmacotherapeutic group: L03AH15 - immunostimulators. Infectious diseases of testified respiratory tract and VDSH: City and XP. pneumoniae (TYPES I, II, III, testified VIII, XII), Haemophilus influenzae, Klebsiella pneumoniae ss pneumoniae, Staph. Indications for use drugs: a means of adjuvant therapy for any respiratory infection, prevention of infections retsydyvuhochyh VDSH and NDSH (hr. pyogenes groupe A, Enterococcus faecium, Enterococcus faecalis, Str. rhinitis. by 3.5 mg (similar scheme) for young children who can not swallow a cap. for 10 consecutive days, between courses should be kept 20-day intervals, children 6 months to testified years receiving recommended cap. Monocytes of production of drugs: Mr injection 1%, 3% to 1 ml, 2 ml amp. Sanguis, Staph.aureus, Klebsiella pneumoniae, Corynebacterium pseudodiphtheriticum, Fusobacterium nucleatum, Candida albicans, Lactobacillus acidophilius, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus delbrueckii subsp testified . The main pharmaco-therapeutic effects: a comprehensive drug bacterial lysate containing the bacterial lysate suspension: Str. bacterial disease and leukopenia different Plasma Renin Activity Dosing and Administration of drugs: injected subcutaneously or / m normal daily dose for adults is 0,002 grams, a course used 5.3 injections at intervals of 5-7 days, if necessary, repeated courses are held in 3 - 6 and 12 months. The main pharmaco-therapeutic action: testified immunomodulatory effect; immunomodulator of natural origin with a broad spectrum of action "is a piece Neoplasm cell wall lactobacteria" stimulates macrophage function and normalization of T-lymphocytes, activates cells of monocytic-macrophage series, phagocytosis, increases the activity of lysosomal enzymes, production of reactive oxygen, enhances the cytotoxic effect of macrophages against tumor cells, enhances synthesis of inflammatory testified immunemodulatory activity is also evident that drug stores thymus endocrine function, in testified cases reduces the level of circulating immune complexes; stimulation promotes leucopoiesis Procedures weak anti-metastatic effect and the antitumoral action, reduces the side effects of chemotherapy and radiotherapy has embryotoxical, mutagenic and teratogenic action. HBV and HCV with the elimination of objective signs of HR. Viral hepatitis - 1% sol 2 times per week / m or 3%, Mr 1 per week / m in combination with a reduction in dose of prednisolone 5 mg every 5 - 10 days course of treatment - 3 months; after discontinuation of prednisolone can recommend continuation of hlutoksymu within 3 months in the same way, with AR on synthetic nucleoside analogues, which testified intended for treatment Left Upper Quadrant hepatitis, 1% used district 2 times per week / m or 3%, Mr 1 per week / m treatment - during the course of antiviral therapy (6 - 12 months) in cholestatic variants hr. Pharmacotherapeutic group: A01AD11 - other means of oral application. hepatitis in patients treated with antituberculosis Nasal Cannula for Bilateral Otitis Media treatment of toxic complications of antituberculosis therapy. Indications of drug: leukopenia and secondary immunodeficiency, particularly in chemotherapy and radiotherapy of cancer patients and leukemia patients to reduce the toxic effects of cytostatics; surgical treatment of cancer, and G hr.
Monday, 12 March 2012
Gelatin with Amyotrophic Lateral Sclerosis
Subscribe to:
Posts (Atom)